Dermatologists achieve cure rates as high as 98% when treating nonaggressive NMSC using SRT for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in select patient populations. SRT is relatively simple to administer, with little impact to underlying healthy tissue. It can be used on any skin surface area and causes minimal scarring. It poses fewer risks than surgery, which is particularly relevant for patients who are elderly or at high risk with significant comorbidities.
Modern SRT devices offer the advantage of relative simplicity, utilizing low energy photon x-rays operating at variable peak voltages of 50 -100 kilovoltage peaks (kVp). The dose delivery is planned and calibrated. The unit automatically stops when the appropriate cumulative amount of radiation is delivered. The SRT is easily administered to target the lesion. The radiation provided is indirect and penetrates to a depth of approximately 5 mm and does not impact the underlying healthy tissue.
It is important to differentiate between SRT used by dermatologists and procedures performed by radiation oncologists (e.g., electron beam, brachytherapy, and electronic brachytherapy) [2,3].
2019 Consensus Guidelines Note the Following:
Presenter disclosures: The presenter has reported relationships with the following companies: Allergan, Inc.; Almirall; Aquavit Pharmaceuticals; Cutera, Inc.; Foamix; Galderma Laboratories, L.P.; Novan; Sebcaia, Inc.; Sensus Healthcare; Sienna Biopharmaceuticals; Stratapharma; Syneron, Inc.
Written by: Daniel Bennett, MPH
Reviewed by: Marina Lambertini, MD